Review article · 28 Apr 2023
Short communicationPublished 27 Oct 2020
Therapeutic plasma exchange; variations on a theme.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Therapeutic plasma exchange (TPE) is an established treatment modality, which can be easily applied in the intensive care unit (ICU). We discern two techniques: centrifugal plasma filtration, by which plasma is separated from whole blood by centrifugal force and membrane plasmaflitration. Membrane plasmafiltration can be easily performed on the conventional hemofiltration machine used for continuous venovenous hemofiltration, in the TPE mode with a special kit in combination with a large pore plasmafilter. Usually 1,5 times the calculated plasma volume will be removed in one session and replaced by a 5 % albumin/saline solution (70/30), fresh frozen plasma (FFP) in case of TTP, or an albumin-FFP mixture. The time interval between procedures and duration of the treatment sessions depend on the patient disease, volume of distribution of the particular substance and a given coagulopathy (1).Toxic substances or auto-antibodies can in this way be removed according to molecule mass and pore width of the filter , so determing the sieving coefficient of that particular substance. Production rate, metabolization rate and protein binding play also an Important role in the clearance of a specific substance. The complications of TPE vary from muscle cramps, urticaria and rarely anaphylaxis or transfusion related acute lung injury (TRALI). As medication is effectively erased from the body, therapeutic drug monitoring is essential (2). There are many publications in literature on TPE but often with a low level of evidence. The American Society for Apheresis (ASFA) has published a list of indications for TPE, ranked after grade of evidence (3). Thrombotic thrombocytopenic purpura (TTP) is a rare life threatening disease with micro-angiopathy due to unrestrained microvascular thrombosis caused by an acquired deficiency of the von Willebrand cleaving factor (Adamst-13). Hemolysis, thrombocytopenia, renal insufficiency and neurological symptoms dominate the clinical picture. If untreated, mortality exceeds 90 % early start of TPE results in survival rates of 20 %(4,5). Immunotherapy with an antibody against the von Willebrand factor is promising if combined with TPE (6). In hemolytic uremic syndrome (HUS) the Shigatoxin, produced by specific Escherchia coli strains (STEC), can result in a similar clinical picture (Stx-HUS) by endothelial damage by the Shigatoxin. Both diseases can be hardly distinguished from each other, and the Adamst 13 may be discriminative . Unfortunately STX-HUS responds less well to TPE. In atypical HUS (a-HUS) ongoing complement activation plays a pivotal role in pathophysiology (7). A well known indication for TPE in hemato-oncology is the hyperviscosity syndrome in case of lymphoplasmocytic syndrome ( M. Waldenström), restoring rheology.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Editorial · 2020
Pharma Sci 2020-Impact of Gender Variation on Calculated Plasma Concentration of Propofol (Cp50calc) to Prevent Movement Response to Surgical Stimulus in South Indian Population: A Comparative Study-Sri Balaji Vidyapeeth (Deemed to be University), India
Conference abstract
Study on variations of Theophylline plasma concentrations with respect to time of administration
Perspective · 29 Aug 2024
Examining Therapeutic Plasma Exchange's Impact on TAFRO Syndrome
Case report · 6 Sep 2022
Severe Hypertriglyceridemia Requiring Therapeutic Plasma Exchange
More from this journal
The newest in Journal of Pharmacology and Medicinal Chemistry.
Editorial · 1 Dec 2022
Effectiveness of specific Indian medicinal plants in terms of medicine and therapy
Commentary · 1 Dec 2022
Modeling of coronary circulation particles for the development of drug carriers
Commentary · 26 Nov 2022
Redefining drug discovery is deep generative molecular design
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacology and Medicinal Chemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Emiel S. Boon”

